His total treatment was five years – the last two of which he was, fortunately, in remission."

24 Apr 2025

Max’s ALL Journey

In June 2008 18-year-old Max England had just finished his A Levels and was looking forward to starting university in the autumn. But it was not to be, as Max started showing strange symptoms which eventually led to a diagnosis of leukaemia. 

“Max went away on a summer vacation with his friends,” said Max’s mum Ann, who now lives in Warsash, Hampshire. “Whilst he was away, he had symptoms of lethargy and one time he fainted. On return from the vacation his lethargy increased to the point he was almost constantly sleeping. Forty-eight hours after he came home we called the doctor. By this time Max was unable to walk to the surgery which was a few miles away and which he normally would have managed easily.” 

The family was living in Bakewell, Derbyshire at the time and Max was immediately sent by ambulance to Royal Hallamshire Hospital in Sheffield where he was given a blood test. Three days later doctors delivered the devastating news to Max and his family that he had acute lymphoblastic leukaemia (ALL). 

“We were so shocked and panicked. Would Max die? Would he live? We just didn’t know. We didn’t know anything much about leukaemia and what the future might hold. In short, we were terrified.” 

Max was kept for the first four weeks in an isolation ward and chemotherapy treatment started immediately.  

Max with Nan, Doreen

“Max’s health fluctuated during this time,” said Max’s dad Steve. “At one point he had a bad reaction to a combination of drugs which led him to have several mini strokes. This in turn led to him losing his speech, which was terrifying. He was on a drugs trial and we learnt that on one previous occasion someone else on the same trial had the same symptoms. The conflicting drugs were rectified and within 24 hours the problem was resolved.” 

Happily, during the last three years of his chemotherapy treatment, Max was at Oxford Brookes University studying for a degree in Planning which he achieved in 2013. Max is now 35 and living life to the full in Teddington, Middlesex, working in London as an estate agent and has regained his health enough to run two London Marathons. He got married in 2023 and he and his wife Katy are expecting their first child in April this year. 

“Strangely Max’s leukaemia was an enriching experience despite the challenges faced,” said Ann. “It made us a very close family unit who appreciated each other for who we are. We had major support from our family and our friends. We took inspiration from Max’s fortitude and the beautiful innocence of his friends from school. Their viewpoint throughout the whole situation was that Max would always be well and so it has proved to be.” 

Related posts

First Medical Research Council and Leukaemia UK Clinical Research Training Fellow shares project highlights

12 June 2021

First Medical Research Council and Leukaemia UK Clinical Research Training Fellow shares project highlights

Dr Sandeep Potluri’s findings will contribute towards a better understanding, cure and treatments of leukaemia and blood cancers

Leukaemia UK appoints new CEO

27 August 2020

Leukaemia UK appoints new CEO

The trustees of Leukaemia UK are delighted to announce that they have appointed Fiona Hazell as CEO of Leukaemia UK. Fiona brings a strong track record in not-for-profit leadership, starting her role on 9th September 2020.

The food industry’s great and good come together to celebrate 25 years of Who’s Cooking Dinner? and raise over £280,000 for leukaemia research.

17 September 2024

The food industry’s great and good come together to celebrate 25 years of Who’s Cooking Dinner? and raise over £280,000 for leukaemia research.

London’s hottest charity culinary event, Who’s Cooking Dinner?, celebrated its 25th anniversary at The Dorchester on Monday (16th September). It was an event to remember with chefs including Tom Kerridge,…

Can the unique differences between stem cells tell us how well CML treatment will work?

22 May 2023

Can the unique differences between stem cells tell us how well CML treatment will work?

What if we could predict how chronic myeloid leukaemia (CML) patients will respond to treatment? Could the unique signatures of CML stem cells hold the key to personalising treatment for…